March 3, 2011 — 9:01am ET By Erica Teichert
Although DMXAA was developed to fight cancer, researchers have found the anti-tumor agent has promising results in flu vaccines via an interferon response.
In a study published in the Journal of Leukocyte Biology, scientists administered two doses of the DMXAA-infused vaccine to infected rats, one dose within three hours of infection and one two days later. Not only did the mice sustain a more mild illness due to the interferon response, the DMXAA vaccine was effective against Tamiflu-resistant strains as well.
Read the rest of the article here.
No comments:
Post a Comment